Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022
Authors
Keywords
-
Journal
JOURNAL OF INFECTION
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-11-04
DOI
10.1016/j.jinf.2023.10.022
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial
- (2023) Xinxue Liu et al. JOURNAL OF INFECTION
- Identifying and alleviating bias due to differential depletion of susceptible people in post-marketing evaluations of COVID-19 vaccines
- (2022) Rebecca Kahn et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses
- (2022) Alexandra C. Walls et al. CELL
- mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
- (2022) Wilfredo F. Garcia-Beltran et al. CELL
- Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants
- (2022) Emma K. Accorsi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
- (2022) Sandile Cele et al. NATURE
- Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
- (2022) Yunlong Cao et al. NATURE
- Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
- (2022) Eddy Pérez-Then et al. NATURE MEDICINE
- Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection
- (2022) Victoria Hall et al. NEW ENGLAND JOURNAL OF MEDICINE
- Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines
- (2022) Nick Andrews et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
- (2022) Heba N. Altarawneh et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein–ACE2 complex
- (2022) Dhiraj Mannar et al. SCIENCE
- Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection
- (2022) John P. Evans et al. Science Translational Medicine
- Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants
- (2022) Timothy A. Bates et al. Science Immunology
- Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity
- (2022) Lauren B. Rodda et al. CELL
- Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2
- (2022) Martin Šmíd et al. JOURNAL OF INFECTIOUS DISEASES
- Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
- (2022) Nick Andrews et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Response 5–7 Months after Vaccination against SARS-CoV-2 in Elderly Nursing Home Residents in the Czech Republic: Comparison of Three Vaccines
- (2022) Jan Martínek et al. Viruses-Basel
- Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
- (2022) Hiam Chemaitelly et al. Nature Communications
- Immune recall improves antibody durability and breadth to SARS-CoV-2 variants
- (2022) Yuezhou Chen et al. Science Immunology
- Immunological memory to SARS‐CoV ‐2 infection and COVID ‐19 vaccines
- (2022) Alessandro Sette et al. IMMUNOLOGICAL REVIEWS
- Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
- (2021) Emma C Wall et al. LANCET
- Hybrid immunity
- (2021) Shane Crotty SCIENCE
- Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
- (2021) Alasdair P S Munro et al. LANCET
- Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
- (2021) Noam Barda et al. LANCET
- Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine
- (2021) Tal Patalon et al. JAMA Internal Medicine
- T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study
- (2021) Adrienn Angyal et al. Lancet Microbe
- IgA dominates the early neutralizing antibody response to SARS-CoV-2
- (2020) Delphine Sterlin et al. Science Translational Medicine
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now